| Moderator 主持 | Giuseppe Tarantini, Kai Xu 徐凯 | |
|
4:00 PM- |
Five year Clinical Outcomes from The PARTNER 3 Trial PARTNER 3 研究五年结果解读 |
Leif Thuesen |
|
4:12 PM- |
Outcomes of Sapien 3 in treating AS: Experience of transfemoral TAVR in 1000 Chinese cases SAPIEN 3球扩瓣中国最新临床结果：上市后中国首1000例AS患者经股TAVR经验 |
Junjie Zhang 张俊杰 |
|
4:24 PM- |
Experience of TAVI in treating Type 0 BAV patients: A multicenter retrospective study from China Type-0型二叶瓣患者中应用球扩式瓣膜行TAVR的临床经验——来自中国的多中心回顾性研究 |
Moyang Wang 王墨扬 |
|
4:48 PM- |
Optimal antithrombotics after TAVR TAVR术后抗栓策略 |
Duk-Woo Park |
|
4:57 PM- |
Coronary access and PCI after TAVI TAVI术后冠脉入路和冠脉介入治疗 |
Radoslaw Parma |
|
5:15 PM- |
Cerebral protection in TAVR-unmet requirement TAVR术中脑保护-未被满足的需求 |
Zhenfei Fang 方臻飞 |